Shell Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $159K | Sell |
1,136
-4,486
| -80% | -$608K | 0.02% | 533 |
|
|
2025
Q2 | $707K | Sell |
5,622
-390
| -6% | -$44.7K | 0.02% | 427 |
|
|
2025
Q1 | $665K | Sell |
6,012
-228
| -4% | -$28.9K | 0.03% | 387 |
|
|
2024
Q4 | $852K | Hold |
6,240
| – | – | 0.04% | 344 |
|
|
2024
Q3 | $719K | Buy |
+6,240
| New | +$855K | 0.03% | 390 |
|
|
2024
Q1 | $885K | Buy |
6,429
+3,496
| +119% | +$477K | 0.04% | 322 |
|
|
2023
Q4 | $386K | Sell |
2,933
-681
| -19% | -$78.4K | 0.02% | 615 |
|
|
2023
Q3 | $407K | Sell |
3,614
-46
| -1% | -$4.84K | 0.02% | 640 |
|
|
2023
Q2 | $345K | Sell |
3,660
-859
| -19% | -$83.9K | 0.01% | 736 |
|
|
2023
Q1 | $457K | Sell |
4,519
-14
| -0.3% | -$1.46K | 0.02% | 593 |
|
|
2022
Q4 | $541K | Sell |
4,533
-811
| -15% | -$95K | 0.02% | 506 |
|
|
2022
Q3 | $568K | Sell |
5,344
-1,257
| -19% | -$128K | 0.02% | 512 |
|
|
2022
Q2 | $643K | Sell |
6,601
-733
| -10% | -$67.7K | 0.02% | 574 |
|
|
2022
Q1 | $688K | Sell |
7,334
-896
| -11% | -$75.9K | 0.02% | 650 |
|
|
2021
Q4 | $701K | Buy |
8,230
+1,371
| +20% | +$126K | 0.01% | 744 |
|
|
2021
Q3 | $658K | Sell |
6,859
-634
| -8% | -$59.9K | 0.01% | 732 |
|
|
2021
Q2 | $729K | Sell |
7,493
-2,953
| -28% | -$283K | 0.01% | 727 |
|
|
2021
Q1 | $1.02M | Sell |
10,446
-10,612
| -50% | -$1.11M | 0.02% | 531 |
|
|
2020
Q4 | $2.02M | Buy |
21,058
+11,654
| +124% | +$1.13M | 0.04% | 381 |
|
|
2020
Q3 | $904K | Hold |
9,404
| – | – | 0.02% | 483 |
|
|
2020
Q2 | $1.15M | Sell |
9,404
-12,008
| -56% | -$1.33M | 0.03% | 414 |
|
|
2020
Q1 | $1.85M | Sell |
21,412
-1,959
| -8% | -$192K | 0.05% | 317 |
|
|
2019
Q4 | $2.51M | Buy |
23,371
+5,427
| +30% | +$568K | 0.05% | 334 |
|
|
2019
Q3 | $1.62M | Sell |
17,944
-2,076
| -10% | -$194K | 0.04% | 389 |
|
|
2019
Q2 | $1.69M | Sell |
20,020
-218
| -1% | -$17.9K | 0.04% | 398 |
|
|
2019
Q1 | $1.78M | Buy |
20,238
+3,482
| +21% | +$291K | 0.04% | 368 |
|
|
2018
Q4 | $1.2M | Sell |
16,756
-3,267
| -16% | -$313K | 0.03% | 450 |
|
|
2018
Q3 | $2.46M | Sell |
20,023
-2,179
| -10% | -$247K | 0.05% | 348 |
|
|
2018
Q2 | $2.18M | Sell |
22,202
-566
| -2% | -$50.7K | 0.04% | 384 |
|
|
2018
Q1 | $1.89M | Buy |
22,768
+5,962
| +35% | +$503K | 0.04% | 407 |
|
|
2017
Q4 | $1.3M | Buy |
16,806
+5,194
| +45% | +$354K | 0.03% | 531 |
|
|
2017
Q3 | $712K | Hold |
11,612
| – | – | 0.02% | 732 |
|
|
2017
Q2 | $534K | Hold |
11,612
| – | – | 0.01% | 885 |
|
|
2017
Q1 | $503K | Sell |
11,612
-3,666
| -24% | -$157K | 0.01% | 904 |
|
|
2016
Q4 | $591K | Hold |
15,278
| – | – | 0.01% | 832 |
|
|
2016
Q3 | $774K | Buy |
15,278
+4,368
| +40% | +$218K | 0.02% | 729 |
|
|
2016
Q2 | $496K | Buy |
+10,910
| New | +$502K | 0.01% | 732 |
|
|
2016
Q1 | – | Sell |
-27,620
| Closed | -$1.56M | – | 904 |
|
|
2015
Q4 | $1.56M | Buy |
+27,620
| New | +$1.4M | 0.04% | 444 |
|
Other funds holding NBIX
Shell Asset Management's NBIX Position: Q3 2025 in Review
Shell Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 80% in Q3 2025, selling an estimated $608K and leaving 1,136 shares worth $159K. The position accounts for 0.02% of the portfolio, ranked #533.
Shell Asset Management first reported a position in NBIX in Q4 2015 and has held it in 38 quarters since. The position peaked at $2.51M in Q4 2019. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.
- Shell Asset Management held 1,136 shares of Neurocrine Biosciences worth $159K as of Q3 2025.
- Shell Asset Management sold 4,486 Neurocrine Biosciences shares in Q3 2025, an estimated $608K.
- Neurocrine Biosciences made up 0.02% of Shell Asset Management's portfolio in Q3 2025, its #533 holding.
- Shell Asset Management first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 38 quarters since.
- Shell Asset Management's Neurocrine Biosciences position peaked at $2.51M in Q4 2019.
- 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.
Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.